Latest News - James Carthew
Carthew: revisiting the most newsworthy trusts of 2017
As 2018 gets underway, I thought that it might be worth revisiting some of the funds that I wrote about in 2017.
Carthew: trusts offering Woodford a lesson in buying AIM minnows
A couple of weeks ago, I was writing about the potential dangers of holding too many early stage and loss-making technology companies in a portfolio
Carthew: the fliers and flops of the trust class of 2017
It has been a fairly busy year for new issues and we still might see a few more make it over the finish line before Christmas
Carthew: Woodford has too many eggs in too few baskets
In a world of quite binary outcomes, diversification seems like a good idea to me.
Carthew: who is next in Bramson's £700m sights?
At the beginning of July 2017, Sherborne Investors C raised £700 million to fund its next battle
James Carthew: is the Japanese glass half full, empty, or illusory?
It is easy to become fixated on Japan's macroeconomic picture.
Carthew: how multi-manager needs to evolve to survive
It has been 10 years since Princess Private Equity listed in London.
Carthew: Biopharma trusts can't resist the double dip
The size and depth of opportunities in healthcare continue to expand
Carthew: complexity killed the ZDP stars
On the face of it, the zero dividend preference market is fading away
Carthew: wait for Brexit blood in the streets to buy property
Why is Hansteen offering to buy back half its issued shares at a premium?
What is the best way to pay wealth managers?
WH Ireland recently joined Charles Stanley in paying its wealth managers based on performance rather than revenue.
Iress: a grand technological wealth design
Efficiency is too often seen as an end in itself, when in reality it should be a natural outcome of a broader approach, writes Richard Ross, digital product manager at Iress.
Mifid II conundrum: how do managers value good research?
A number of brokers, including WH Ireland, have been able to put out their research for free.